SecurAcath Significantly Reduces Catheter-Related Infection Risk

Published Article in the American Journal of Infection Control. Open Access June 17, 2020.

Saturday, July 11, 2020

Today, Interrad Medical, a privately held medical device company, announced a new clinical data publication that shows a significantly lower catheter-related infection risk with the use of the SecurAcath Subcutaneous Catheter Securement Device.

The article titled: Catheter Securement Impact on PICC-related CLABSI: A University Hospital Perspective, Rowe, et al, was published in the American Journal of Infection Control, Open Access, June 17, 2020.

This retrospective, observational quality review performed at the University of Arkansas for Medical Sciences (UAMS) analyzed 7,779 patients over four years of Central Line-Associated Bloodstream Infection (CLABSI) data. This study sought to understand the impact of securement devices on the CLABSI rate in patients who had PICCs. Analysis compared outcomes of patients whose PICCs were secured with the SecurAcath to those secured with an adhesive device.

The study found a substantial difference in relative risk among securement devices utilized in their population. The analysis showed those who had an adhesive device had a 288% increase in risk of CLABSI compared to those who had a SecurAcath. The difference in practice demonstrated direct positive impact on patient outcomes when using SecurAcath versus an adhesive securement device.

The occurrence of CLABSIs yield tremendous negative consequences affecting patients and health care facilities associated with morbidity, mortality, and financial burdens. The CDC estimates the annual cost of CLABSI is more than $1 billion, the cost per patient is more than $16,000.

Mark Rowe, MNSc, RNP, VA-BC, Sr. Vascular Access Specialist, UAMS, stated, “We have been very pleased with the improved catheter securement and reduced complications with the SecurAcath including lower CRBSI risk, catheter dislodgements, and line replacements.”

“This important and exciting new infection reduction data supports the fact that the SecurAcath improves outcomes, increases efficiencies, and lowers the cost of patient care,” commented Joe Goldberger, President, and CEO of Interrad Medical.

The SecurAcath is the only subcutaneous catheter securement device that lasts the life of the line and can reduce catheter-related infections and other complications, dramatically decrease catheter dislodgement and migration, decrease catheter replacement costs, and lower total cost of patient care.

 

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc.

WE WELCOME YOUR VIEWS

Please enter your comment!
Please enter your name here